{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:19:47Z","timestamp":1770218387352,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd001717","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2005,7,20]],"date-time":"2005-07-20T00:00:00Z","timestamp":1121817600000}}],"reference-count":43,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001717.pub2","type":"journal-article","created":{"date-parts":[[2005,7,4]],"date-time":"2005-07-04T13:18:45Z","timestamp":1120483125000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Depot perphenazine decanoate and enanthate for schizophrenia"],"prefix":"10.1002","volume":"2009","author":[{"given":"Anthony","family":"David","sequence":"first","affiliation":[{"name":"Institute of Psychiatry; De Crespigny Park BOX PO68 London UK SE5 8AF"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema N","family":"Quraishi","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry; De Crespigny Park BOX PO68 London UK SE5 8AF"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Rathbone","sequence":"additional","affiliation":[{"name":"Institute of Mental Health; Cochrane Schizophrenia Group; Gateway Building, University of Nottingham Innovation Park, Triumph Road Nottingham UK NG7 2TU"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,7,20]]},"reference":[{"key":"10.1002\/14651858.CD001717.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1600-0447.1980.tb07085.x","article-title":"Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients","volume":"61","author":"Ahlfors","year":"1980","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0002|cit2","first-page":"534","article-title":"Double blind compartive trial with 2 depot neuroleptics (perphenazine enanthate and fluphenthixol decanoate with chronic schizophrenia","volume":"50","author":"Eufe","year":"1979","journal-title":"Nervenarzt"},{"issue":"supp 322","key":"10.1002\/14651858.CD001717.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0447.1985.tb08537.x","article-title":"Perphenazine decanoate vs perphenazine enanthate efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients","volume":"72","author":"Knudsen","year":"1985","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"5","key":"10.1002\/14651858.CD001717.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1055\/s-0028-1094631","article-title":"A comparative study of the longacting neuroleptics perphenazin enanthate and fluspirilene","volume":"12","author":"Tegeler","year":"1979","journal-title":"Pharmakopsychiatrie Neuropsychopharmakologie"},{"issue":"2","key":"10.1002\/14651858.CD001717.pub2-BIB0005|cit5","first-page":"267","article-title":"Clinical study on five depot neuroleptics. Comparison of effective profiles of fluphenazine decanoate, fluspirilene, penfluridol, perphenazine enanthate and pipothiazine palmitate","volume":"25","author":"Angst","year":"1975","journal-title":"Arzneimittel Forschung"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0447.1973.tb08446.x","article-title":"Clinical experience with depot neuroleptics","volume":"246","author":"Bakke","year":"1973","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/BF02245440","article-title":"A long term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanaote in schizophrenic patients","volume":"114","author":"Dencker","year":"1994","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD001717.pub2-BIB0008|cit8","first-page":"7","article-title":"Clinical profiles of action, individual treatment preferences, affects and contraindications of three depot neuroleptics compared in a multicentre trial","volume":"25","author":"Giannelli","year":"1990","journal-title":"Rivista di Psichiatria"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/BF02316862","article-title":"Perphenazine decanoate and cis(z)-flupenthixol decanoate in maintenance treatment of schizophrenic outpatients","volume":"105","author":"Kistrup","year":"1991","journal-title":"Psychopharmacology"},{"issue":"supp 322","key":"10.1002\/14651858.CD001717.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-0447.1985.tb08538.x","article-title":"Long-term depot neuroleptic treatment with perphenazine decanoate I","volume":"76","author":"Knudsen","year":"1985","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"supp 322","key":"10.1002\/14651858.CD001717.pub2-BIB0011|cit11","first-page":"40","article-title":"Long-term depot neuroleptic treatment with perphenazine decanoate II","volume":"76","author":"Knudsen","year":"1985","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"supp 322","key":"10.1002\/14651858.CD001717.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1985.tb08536.x","article-title":"Perphenazine decanoate in sesame oil vs perphenazine enanthate in sesame oil","volume":"76","author":"Knudsen","year":"1985","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00426949","article-title":"Effects of perphenazine enanthate injections on rolactin levels in plasma from schizophrenic women and men","volume":"57","author":"Lindholm","year":"1978","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-0028-1094349","article-title":"Preliminary study of perphenazine enanthate in the treatment of chronic schizophrenia","volume":"5","author":"Rapp","year":"1972","journal-title":"Pharmakopsychiatrie Neuro Psychopharmakologie"},{"issue":"5","key":"10.1002\/14651858.CD001717.pub2-BIB0015|cit15","first-page":"665","article-title":"A double blind crossover study comparing haloperidol decanoate and perphanazine enantate","volume":"39","author":"Rapp","year":"1986","journal-title":"Current Therapeutic Research"},{"issue":"4","key":"10.1002\/14651858.CD001717.pub2-BIB0016|cit16","first-page":"227","article-title":"Experience with perphenazine-enanthate in the maintenance therapy of schizophrenic psychoses","volume":"24","author":"Rysanek","year":"1982","journal-title":"Activas Nervosa Superior (Praha)"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0017|cit17","unstructured":"Aaes-Jorgenson A Pharmacokinetics of oral and depot neuroleptics-Clinical relevance Symposium Espo"},{"issue":"Issue 1","key":"10.1002\/14651858.CD001717.pub2-BIB0018|cit18","article-title":"Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]","author":"Alderson","year":"2004","journal-title":"The Cochrane Library"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD001717.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2165\/00002018-199410060-00005","article-title":"Long term depot antipsychotics. A risk benefit assessment","volume":"10","author":"Barnes","year":"1994","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1192\/bjp.146.5.464","article-title":"Long-term depot maintenance of chronic schizophrenic out-patients: the seven-year follow-up of the medical research council fluphenazine\/ placebo trial","volume":"146","author":"Curson","year":"1985","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0023|cit23","volume-title":"The neuropsychology of schizophrenia","author":"David","year":"1994"},{"issue":"suppl 1","key":"10.1002\/14651858.CD001717.pub2-BIB0024|cit24","first-page":"2","article-title":"The natural course of schizophrenia and effective maintenance drug therapy","volume":"6","author":"Davis","year":"1986","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"supp 279","key":"10.1002\/14651858.CD001717.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1600-0447.1980.tb07084.x","article-title":"Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study","volume":"61","author":"Dencker","year":"1980","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"6","key":"10.1002\/14651858.CD001717.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0027|cit27","unstructured":"Department of Health NHS Executive Burdens of disease: a discussion document HMSO 1996"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0031|cit31","first-page":"124","volume-title":"ECDEU Assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0032|cit32","volume-title":"Compliance in health care","author":"Haynes","year":"1979"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.1.5854.633","article-title":"Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo controlled trial","volume":"1","author":"Hirsch","year":"1973","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0264180100000904","article-title":"Schizophrenia: manifestations, incidence and course indifferent cultures. A World Health Organization ten-country study","volume":"20","author":"Jablensky","year":"1992","journal-title":"Psychological Medicine (Monograph Supplement)"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0924-977X(97)00045-X","article-title":"Guidelines for depot antipsychotic treatment in schizophrenia","volume":"8","author":"Kane","year":"1998","journal-title":"European Neuropschopharmacology"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD001717.pub2-BIB0040|cit40","first-page":"303","article-title":"Chronic schizophrenia treated with depot perphenazine","volume":"25","author":"Petersson","year":"1971","journal-title":"Nordic Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.1994.03520020051014","article-title":"Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals","volume":"272","author":"Schulz","year":"1994","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD001717.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0895-4356(94)00141-C","article-title":"Cost-effectiveness comparisons using \"real world\" randomized trials: the case of new antidepressant drugs","volume":"48","author":"Simon","year":"1995","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD001717.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD001717.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T18:47:16Z","timestamp":1764701236000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001717.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2005,7,20]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2009,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001717.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,20]]}}}